Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA-affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, direct delivery of AAV to the CNS was well tolerated in animal models [185, 186].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 5×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
InfluentialSelf-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Lentiviral vector–mediated transduction of autologous CD34+ HSCs has shown therapeutic efficacy in adrenoleukodystrophy (12), and Authorship note: Virginia Haurigot and Sara Marcó contributed equally to this work.”
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 12×
“Asymmetrical distribution of AAV-neutralizing antibodies across the BBB .”
InfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Alternatively, AAV9, a serotype recently isolated from human tissue (25), has been shown to have broad tropism and to cross the BBB after systemic administration (26, 27), reverting the neurological phenotype of MPS IIIB (28) and MPS IIIA (29) mice.”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 4×
“…serum NAb titers greater than 1:1,000) and given that only a small proportion of humans will present with very high anti-AAV9 antibody titers (41), GFP expression was detected throughout the CNS, particularly in the leptome-ninges in both injected animals (Figure 11, A and B), though at what…”
InfluentialTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 2×
“In vivo gene therapy offers the possibility of a one-time treat-ment for MPS IIIA and other inherited diseases, with the prospect of lifelong beneficial effects (14).”
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
Self-citationInagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610 · cited 1×
“Additionally, AAV9 vectors delivered into the bloodstream efficiently transduce several peripheral tissues, such as liver, heart, and skeletal muscle, demonstrating a broad distribution profile (27, 32).”
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511 · cited 4×
“Additionally, AAV9 vectors delivered into the bloodstream efficiently transduce several peripheral tissues, such as liver, heart, and skeletal muscle, demonstrating a broad distribution profile (27, 32).”
Influential
Research works printed but not linked: 1
- Hemsley, 2009, Int J Clin Pharmacol Ther., 47, S118
Cited by
Items 101–200 of 223
A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise
Pearse, Y., & Iacovino, M. (2020) · Medical Research Archives · doi:10.18103/mra.v8i2.2045 · Cited by 40
Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery
Pietersz, K. L., Martier, R., Baatje, M. S., Liefhebber, J. M. P., Brouwers, C. C., Pouw, S. M., Fokkert, L., Lubelski, J., Petry, H., Martens, G. J. M., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0178-0 · Cited by 41
Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease
Bradbury, A. M., Gray‐Edwards, H. L., Shirley, J. L., McCurdy, V. J., Colaço, A., Randle, A. N., Christopherson, P. W., Bird, A. C., Johnson, A. K., Wilson, D. U., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.020 · Cited by 39
“Partial correction of the periphery after intracranial delivery of gene therapy has been described in mice with mucopolysaccharidosis IIIA (Haurigot et al., 2013) and neuronal ceroid lipofuscinosis (Sondhi et al.”
InfluentialThe Application of Adeno-Associated Viral Vector Gene Therapy to the Treatment of Fragile X Syndrome
Hampson, D. R., Hooper, A. W. M., & Niibori, Y. (2019) · Brain Sciences · doi:10.3390/brainsci9020032 · Cited by 40
Sellers, D. L., Bergen, J. M., Johnson, R. N., Back, H., Ravits, J., Horner, P. J., & Pun, S. H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515526113 · Cited by 40
“More recently, intrathecal administration of AAV into the cerebral spinal fluid (CSF) has been shown to be effective in gene transfer to the CNS in nonhuman primates (11, 12) and has also been used in clinical trials to deliver engineered cells acting as protein expression depots (13).”
BackgroundA Review of Gene Therapy in Canine and Feline Models of Lysosomal Storage Disorders
Bradbury, A. M., Gurda, B. L., Casal, M. L., Ponder, K. P., Vite, C. H., & Haskins, M. E. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.002 · Cited by 44
Marcó, S., Haurigot, V., & Bosch, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.217 · Cited by 39
“51,119 As a result, the pattern of vector transduction differs considerably from that obtained following intraparenchymal injection at multiple sites, which results in uneven distribution of vector genomes, with high copy numbers at the point of injection quickly decreasing with distance.”
InfluentialSelf-citationAdeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain
Swain, G. P., Prociuk, M. L., Bagel, J. H., O’Donnell, P., Berger, K., Drobatz, K., Gurda, B. L., Haskins, M. E., Sands, M. S., & Vite, C. H. (2013) · Gene Therapy · doi:10.1038/gt.2013.54 · Cited by 39
Hocquemiller, M., Hemsley, K. M., Douglass, M. L., Tamang, S. J., Neumann, D., King, B. M., Beard, H., Trim, P. J., Winner, L. K., Lau, A. A., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.001 · Cited by 34
Chen, X., Snanoudj-Verber, S., Pollard, L., Hu, Y.-H., Cathey, S., Tikkanen, R., & Gray, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.012 · Cited by 30
Gray‐Edwards, H. L., Brunson, B. L., Holland, M., Hespel, A., Bradbury, A. M., McCurdy, V. J., Beadlescomb, P. M., Randle, A. N., Salibi, N., Denney, T. S., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.05.003 · Cited by 32
“This hypothesis is supported by the observation that the greatest correction of GAG storage was in the liver, which is exposed to a large circulatory volume and is among themost highly transduced peripheral tissues after CSF [22,25] or direct intravascular injection [59].”
BackgroundInfluentialClinical Improvement of Alpha-mannosidosis Cat Following a Single Cisterna Magna Infusion of AAV1
Yoon, S. Y., Bagel, J. H., O’Donnell, P. A., Vite, C. H., & Wolfe, J. H. N. (2015) · Molecular Therapy · doi:10.1038/mt.2015.168 · Cited by 34
Hironaka, K., Yamazaki, Y., Hirai, Y., Yamamoto, M., Miyake, N., Miyake, K., Okada, T., Morita, A., & Shimada, T. (2015) · Scientific Reports · doi:10.1038/srep13104 · Cited by 33
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 32
Timing of Gene Therapy Interventions: The Earlier, the Better
Gray, S. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.20 · Cited by 29
AAV-mediated BMP7 gene therapy counteracts insulin resistance and obesity
Casana, E., Jiménez, V., Jambrina, C., Sacristan, V., MUÑOZ, S. A., Rodó, J., Grass, I., García, M., Mallol, C., León, X., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.007 · Cited by 29
Self-citationHinderer, C. J., Nosratbakhsh, B., Katz, N., & Wilson, J. M. (2020) · Human Gene Therapy · doi:10.1089/hum.2018.206 · Cited by 29
“Pre-existing neutralizing antibodies to the vector capsid do not impact gene transfer to the brain, but may prevent peripheral transduction, potentially leading to different degrees of peripheral b-gal expression in patients depending on neutralizing antibody status.(11,12) This study demonstrated an absence of neuron…”
BackgroundPre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases
Favret, J., Weinstock, N. I., Feltri, M. L., & Shin, D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00057 · Cited by 31
“This animal has been used for GT and SRT studies which have successfully extended mutant lifespan and reduced associated symptomology (McIntyre et al., 2008; Roberts et al., 2010; Haurigot et al., 2013).”
MethodEmerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders
Limia, C. E. G., Baird, M., Schwartz, M., Saxena, S., Meyer, K., & Wein, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121979 · Cited by 31
Marcó, S., Pujol, A., Roca, C., Motas, S., Ribera, A., Garcia, M., Molas, M., Villacampa, P., Melia, C. S., Sánchez, V., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025171 · Cited by 33
“…alterations were in line with those previously observed by several other groups in two different mouse models of Sanfilippo disease (Fraldi et al., 2007; Haurigot et al., 2013; Hemsley and Hopwood, 2005; Lau et al., 2008; Li et al., 1999; McIntyre et al., 2010, 2014; Ribera et al., 2015).”
InfluentialSelf-citationHutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Gene delivery strategies for the treatment of mucopolysaccharidoses
Baldo, G., Giugliani, R., & Matte, Ú. D. S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.880689 · Cited by 27
“Other studies have also shown improvements in several parameters after in situ injection [17-19] with good results, particularly for MPS III, but one study stands out in particular because it suggests that an intracerebrospinal fluid injection corrected not only the brain pathology but also the somatic features presen…”
BackgroundDuncan, F. J., Naughton, B. J., Zaraspe, K., Murrey, D. A., Meadows, A. S., Clark, K. R., Newsom, D. E., White, P., Fu, H., & McCarty, D. M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.9 · Cited by 25
Gene therapy for the neurological manifestations in lysosomal storage disorders
Cheng, S. H. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r047175 · Cited by 26
McIntyre, C., Derrick‐Roberts, A. L. K., Byers, S., & Anson, D. S. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2816 · Cited by 26
“According to the animal studies performed so far, the ependymal cells lining the lateral ventricles, and other internal fluid filled areas within the brain, do not present a barrier to lysosomal enzymes or appropriately serotyped/pseudotyped viral vectors [28,44,46,49,50] and evidence that therapeutic agents can be wi…”
BackgroundInfluentialLüscher, C., Emiliani, V., Farahany, N. A., Gittis, A. H., Gradinaru, V., High, K. A., Roska, B., Sahel, J., Yizhar, O., Zeng, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02097-9 · Cited by 30
“Perspective https://doi.org/10.1038/s41593-025-02097-9 (with some serotypes more likely to leak than others 124 ).”
InfluentialAdvances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders
Zhou, L., Wang, Y., Xu, Y., Zhang, Y., & Zhu, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101357 · Cited by 26
Inner Ear Gene Therapy: An Overview from Bench to Bedside
Gadenstaetter, A. J., Krumpoeck, P. E., & Landegger, L. D. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00759-1 · Cited by 24
Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing
Odermatt, P., TRUEB, J., Furrer, L., Fricker, R., Marti, A., & Schümperli, D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.152 · Cited by 26
Markmann, S., Christie-Reid, J. J., Rosenberg, J. B., De, B. P., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.04.001 · Cited by 24
Lot-to-Lot Variation in Adeno-Associated Virus Serotype 9 (AAV9) Preparations
O'Connor, D. M., Lutomski, C. A., Jarrold, M. F., Boulis, N. M., & Donsante, A. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.105 · Cited by 23
Pleticha, J., Heilmann, L. F., Evans, C. H., Asokan, A., Samulski, R. J., & Beutler, A. S. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-54 · Cited by 21
“[34] demonstrated only moderately reduced CNS- and PNS transduction rates for NAb titers as high as 1:1000, suggesting that an immune privilegelike status may apply to the PNS.”
BackgroundMethodInfluentialGustavsson, S., Sjöström, E. O., Tjernberg, A., Janson, J., Westermark, U., Andersson, T., Makower, Å., Arnelöf, E., Andersson, G., Svartengren, J., et al. (2019) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2019.100510 · Cited by 24
Belur, L. R., Podetz-Pedersen, K. M., Tran, T., Mesick, J. A., Singh, N. M., Riedl, M., Vulchanova, L., Kozarsky, K., & McIvor, R. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100604 · Cited by 22
Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis
Gross, A. L., Gray‐Edwards, H. L., Bebout, C. N., Ta, N. L., Nielsen, K., Brunson, B. L., Mercado, K. R. L., Osterhoudt, D. E., Batista, A. R., Maitland, S. A., et al. (2021) · Brain · doi:10.1093/brain/awab309 · Cited by 21
Lau, A. A., King, B. M., Thorsen, C. L., Hassiotis, S., Beard, H., Trim, P. J., Whyte, L. S., Tamang, S. J., Duplock, S. K., Snel, M. F., et al. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0044-4 · Cited by 20
Rasmussen, C. L. M., Hede, E., Routhe, L. G., Körbelin, J., Helgudóttir, S. S., Thomsen, L. B., Schwaninger, M., Burkhart, A., & Moos, T. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15621 · Cited by 20
“…to the brain Several studies exploring AAV viral- based gene therapy in the brain rely on intracerebral injection attempting to ensure delivery to the brain with the avoidance of peripheral off- target effects (Bey et al., 2017; Haurigot et al., 2013; Hughes et al., 2018; Markmann et al., 2018).”
BackgroundDonsante, A., McEachin, Z. T., Riley, J. S., Leung, C. H., Kanz, L., O’Connor, D. M. A., & Boulis, N. M. (2016) · Gene Therapy · doi:10.1038/gt.2016.6 · Cited by 19
Hede, E., Christiansen, C. B., Heegaard, C., Moos, T., & Burkhart, A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14982 · Cited by 14
“…with systemic involvements following intracisternal administration of gene therapies (Bey et al., 2017; Gray, Nagabhushan, McCown, & Jude, 2013; Haurigot et al., 2013; Markmann, J. Christie-Reid J., Rosenberg J. B., De B. P., Kaminsky S. M., Crystal R. G., & Sondhi D., 2018; Roca et al., 2017).”
Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA
Sorrentino, N. C., Cacace, V., Risi, M. D., Maffia, V., Strollo, S., Tedesco, N., Nusco, E., Romagnoli, N., Ventrella, D., Huang, Y., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.009 · Cited by 18
“Intra-cerebrospinal fluid (CSF) administration allows circulating virus to reach a large CNS surface area, and at the same time provides access to visceral organs due to the leakage of vector into the bloodstream.(9,16,17) Among different AAV serotypes, serotype 9 has been shown to have a broad tropism, including neur…”
BackgroundHocquemiller, M., Giersch, L., Mei, X., Gross, A. L., Randle, A. N., Gray‐Edwards, H. L., Hudson, J. A., Todeasa, S. H., Stoica, L., Martin, D. R., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.004 · Cited by 20
“Similar asymptomatic vector-induced microscopic changes in sensory pathways were previously described in toxicology studies in NHP following AAV vector administration into the blood or CSF.18,25–27,29 Dorsal root ganglia (DRG) neurons in monkeys and pigs seem to be more sensitive to AAV-induced DRG toxicity than other…”
InfluentialSorrentino, N. C., Maffia, V., Strollo, S., Cacace, V., Romagnoli, N., Manfredi, A., Ventrella, D., Dondi, F., Barone, F., Giunti, M., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.212 · Cited by 19
Yi, F., Hong, X., Kumar, A. B., Zong, C., Boons, G., Scott, C. R., Tureček, F., Robinson, B. H., & Gelb, M. H. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.05.005 · Cited by 18
“Mucopolysaccharidosis III type A (MPS-IIIA) is an autosomal recessive inherited disease with no current treatment; however, intra-cerebrospinal fluid gene therapy and intrathecal enzyme replacement therapy have shown promising early clinical results [1,2].”
BackgroundOvercoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
Chen, Y., Shujuan, Z., Tecedor, L., & Davidson, B. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.010 · Cited by 17
MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV
DeRosa, S., Salani, M., Smith, S., Sangster, M., Miller-Browne, V., Wassmer, S., Xiao, R., Vandenberghe, L. H., Slaugenhaupt, S. A., Misko, A. L., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab093 · Cited by 17
Chang, H., Lee, Y., Javed, S., Haque, M., Chang, Y.-T., Lin, Y. C., Oram, C., & Huang, W. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102728 · Cited by 19
“To avoid triggering systemic inflammatory toxicities associated with systemic rAAV injection (18,42-44), we locally administered rAAV and observed”
MethodMcCurdy, V. J., Johnson, A. K., Gray‐Edwards, H. L., Randle, A. N., Bradbury, A. M., Morrison, N. E., Hwang, M., Baker, H. J., Cox, N. R., Sena‐Esteves, M., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-00190-1 · Cited by 17
Jiménez, V., Sacristan, V., Jambrina, C., Jaén, M. L., Casana, E., MUÑOZ, S. A., Marcó, S., Molas, M., García, M., Grass, I., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.023 · Cited by 16
Self-citationGene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
de Castro, M. J., del Toro, M., Giugliani, R., & Couce, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179200 · Cited by 17
MPS‐IIIA mice acquire autistic behaviours with age
Lau, A. A., Tamang, S. J., & Hemsley, K. M. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0160-9 · Cited by 16
Saville, J. T., Derrick‐Roberts, A. L. K., McIntyre, C., & Fuller, M. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.253 · Cited by 16
“21,22 Given relative differences could still be observed, and due to the limited sample available, we were unable to perform a background subtraction for each sample.”
Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art
Consiglieri, G., Bernardo, M. E., Brunetti‐Pierri, N., & Aiuti, A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.012 · Cited by 15
Niemir, N., Rouvière, L., Besse, A., Vanier, M. T., Dmytrus, J., Marais, T., Astord, S., Puech, J.-P., Panasyuk, G., Cooper, J. D., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy012 · Cited by 17
Rosenberg, J. B., Fung, E. K., Dyke, J. P., De, B. P., Lou, H., Kelly, J. M., Reejhsinghani, L., Arbona, R. J. R., Sondhi, D., Kaminsky, S. M., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.060 · Cited by 15
High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs
Pleticha, J., Malkmus, S. A., Heilmann, L. F., Veesart, S. L., Rezek, R., Xu, Q., Yaksh, T. L., & Beutler, A. S. (2014) · Gene Therapy · doi:10.1038/gt.2014.96 · Cited by 13
Kot, S., Karumuthil‐Melethil, S., Woodley, E., Zaric, V., Thompson, P., Chen, Z., Lykken, E. A., Keimel, J. G., Kaemmerer, W. F., Gray, S. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136751 · Cited by 15
Vono, M., del Rio, T., Magdaleno, E., Loll, N. R., Jarvis, P., Walter, C., Kikkawa, R., Mansfield, K., McBlane, F., Sirivelu, M. P., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101602 · Cited by 11
“23 This finding has since been verified with other AAV serotypes, including AAV5.”
Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
O’Leary, C., Forte, G., Mitchell, N. L., Youshani, A. S., Dyer, A. S., Wellby, M. P., Russell, K. N., Murray, S. J., Jolinon, N., Jones, S. A., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04208-1 · Cited by 12
Gilkes, J. A., Bloom, M. D., & Heldermon, C. D. (2015) · Gene Therapy · doi:10.1038/gt.2015.111 · Cited by 11
“32– 34 Furthermore, differences in transduction of astrocytes by rAAVs expressing secreted neurotrophic factors may be beneficial for a number of neurodegenerative diseases with astrocyte atrophy or deficiencies such as Amyotrophic Lateral Sclerosis and Alzheimer's disease.”
Pagès, G., Giménez‐Llort, L., García-Lareu, B., Ariza, L., Navarro, M., Casas, C., Chillón, M., & Bosch, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz220 · Cited by 10
Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space
Wang, D., Li, J., Tran, K., Burt, D. R., Li, Z., & Gao, G. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.250 · Cited by 10
Lundstrom, K. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00002-x · Cited by 11
Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration
Lau, A. A., & Hemsley, K. M. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1562-0 · Cited by 9
“The effect of 5 × 10(9) or 5 × 10(10) vg of AAV9-murine Sgsh under the control of the ubiquitous CAG promoter (hybrid of the chicken β-actin promoter and CMV enhancer), injected into the CSF of 8-week-old MPS-IIIA mice was subsequently evaluated [78].”
BackgroundMethodHoriuchi, M., Hinderer, C. J., Greig, J. A., Dyer, C., Buza, E. L., Bell, P. L., Chichester, J. A., Hayashi, P. M., Yan, H., Goode, T. L., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.017 · Cited by 9
Parente, A., Borzacchiello, L., Marianna, G., Bamundo, M., Rubino, R., D’Auria, L., Monaco, A., & Fraldi, A. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109224 · Cited by 9
Podetz-Pedersen, K. M., Laoharawee, K., Singh, S. M., Nguyen, T. T. T. N., Smith, M. C., Temme, A., Kozarsky, K., McIvor, R. S., & Belur, L. R. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.162 · Cited by 9
“28,43 Blood was therefore collected from animals to test for IDUA or IDS levels in plasma.”
Mateu-Bosch, A., Segur‐Bailach, E., Muñoz‐Moreno, E., Barallobre, M. J., Arbonés, M. L., Gea‐Sorlí, S., Tort, F., Ribes, A., García‐Villoria, J., & Fillat, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101276 · Cited by 9
“18,19 Since GCDH de fi ciency mostly leads to neuropathological alterations, we selected the AAV serotype AAV9 for its widespread transduction of the CNS parenchyma and its ability to cross the blood-brain barrier after intravascular delivery.”
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 9
Johnson, A. K., McCurdy, V. J., Gray‐Edwards, H. L., Maguire, A. S., Cochran, J. N., Gross, A. L., Skinner, H. E., Randle, A. N., Shirley, J. L., Brunson, B. L., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26756 · Cited by 9
AAV gene replacement therapy for treating MPS IIIC: Facilitating bystander effects via EV‐mRNA cargo
Bobo, T. A., Robinson, M. J., Tofade, C., Sokolsky‐Papkov, M., Nichols, P., Vorobiov, S., & Fu, H. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12464 · Cited by 7
Marianna, G., Monaco, A., Laura, G., Parente, A., Borzacchiello, L., Riccardo, R., Frank-Gerrit, K., Dennis, K., Perna, C., Piccolo, P., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.030 · Cited by 7
“Although previously the AAV9-SGSH and CLR01 therapies have been shown to be safe in preclinical animal models, 41,48,49 to address whether together they might have caused unexpected safety concern, we evaluated the safety of the combination therapy.”
Abreu, N. J., Selvaraj, B., Truxal, K. V., Moore‐Clingenpeel, M., Zumberge, N. A., McNally, K. A., McBride, K. L., Ho, M., & Flanigan, K. M. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.04.006 · Cited by 7
Toward a gene therapy for neurological and somatic MPSIIIA
Haurigot, V., & Bosch, F. (2013) · Rare Diseases · doi:10.4161/rdis.27209 · Cited by 9
“Moreover, the degree of neuropathy is such at 2 mo of age that animals show clear behavioral abnormalities in the open field test,(40) the same test by which we demonstrated normalization of behavior in treated MPSIIIA mice four months after intra-CSF AAV9sulfamidase treatment.(6) The treatmentmediated correction of b…”
BackgroundMethodResultSelf-citationLee, M. H., Kang, S., Um, K. H., Lee, S. W., Hwang, H., Baek, K., & Choi, J. W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04816-x · Cited by 7
“Prior reports have suggested that, when utilizing AAV gene therapy with local injections, the intended gene does not express exclusively at the site of injection but distributes throughout the entire organ [30].”
BackgroundHunter, J. E., Vite, C. H., Molony, C. M., O’Donnell, P. A., & Wolfe, J. H. N. (2024) · Gene Therapy · doi:10.1038/s41434-024-00510-9 · Cited by 7
“In contrast, other studies have performed ICV injections using GFP-expressing AAVs in both normal and Krabbe disease dogs without incident [16, 17].”
Riboflavin transporter deficiency: AAV9-SLC52A2 gene therapy as a new therapeutic strategy
Mei, C., Magliocca, V., Chen, X., Massey, K., Gonzalez-Cordero, A., Gray, S., Tartaglia, M., Bertini, E., Corti, S., & Compagnucci, C. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1523773 · Cited by 4
Muramatsu, S., Hwu, W., & Gidoni-Ben-Zeev, B. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210922155413 · Cited by 6
Laoharawee, K., Podetz-Pedersen, K. M., Nguyen, T. T. T. N., Singh, S. M., Smith, M. C., Belur, L. R., Low, W. C., Kozarsky, K., & McIvor, R. S. (2023) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2023.100956 · Cited by 10
“The administration of rAAV9 vector to mediate gene transfer has been successfully evaluated in several preclinical models of lysosomal storage disorders [23,26,28,38], emphasizing its potential translation to clinical application.”
BackgroundAAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Self-citationHow does “Protein Corona” Affect the In vivo Efficiency of Polymeric Nanoparticles? State of Art
(2017) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681084930117020011 · Cited by 6
Evola, V., & Parmar, M. S. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2647033 · Cited by 4
“Notably, CSF-based delivery may also offer an immunological advantage, as NAbs against viral vectors (e.g. AAV2 and AAV9) are typically present at much lower levels in the CSF than in the serum [90,91].”
Beard, H., Winner, L. K., Shoubridge, A. P., Parkinson-Lawrence, E. J., Lau, A. A., Mubarokah, S. N., Lance, T., King, B. M., Scott, W., Snel, M. F., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14919 · Cited by 3
“In contrast, Haurigot et al. 8 and the abovementioned Batten disease model studies have shown that intra-CSF infusion of AAV9-based gene replacement leads to transduction of brain, spinal cord, and pe - ripheral nervous system, e.g., peripheral ganglia, together with other organs; however, there is…”
Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep
Taghian, T., Gallagher, J., Bertrand, S., Baker, W. C., Mercado, K. R. L., Benatti, H. R., Hall, E. F., Lopez, Y., McElroy, A. W., McCarthy, J. T., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci182942 · Cited by 3
“This delivery approach has yielded impressive results for neuronopathic lysosomal storage diseases in which the AAV-encoded transgene is a secreted soluble enzyme that can be subsequently taken up by nontransduced cells via the mannose-6-phosphate receptor on the cell surface (29, 33–39).”
Wang, P., Zhao, G., Ji, Y., Zhang, P., Zhang, X., Gong, J., Zhao, L., Yan, Z., Yin, M., Jiang, Z., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0063-1 · Cited by 3
Rybarikova, M., Almacellas‐Barbanoj, A., Schorge, S., & Déglon, N. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.177 · Cited by 2
“This vector might be of particular interest for application to certain neurological diseases, including mucopolysaccharidosis type IIIA, 45 Batten disease 46 or MLD 47 for its strong tropism for ependymal cells and choroid plexus.”
Magat, J., Jones, S., Baridon, B., Agrawal, V., Wong, H., Giaramita, A., Mangini, L., Handyside, B., Vitelli, C., Parker, M., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102625 · Cited by 2
“Gene therapies have also been delivered directly to the CNS or administered peripherally in mice (15-21) and humans (22).”
BackgroundUnger, M., Pleticha, J., Heilmann, L. F., Newman, L. K., Maus, T. P., & Beutler, A. S. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3026 · Cited by 2
“Such xenogeneic immunity appears to occur in many large animal models (and potentially not to the same degree in rodents), as reported previously.(10,20) Although xenogeneic immunity likely contributed to the sustained decline in CSF IL‐10 levels, an additional possibility is that the CMVpromoter may have been silence…”
ResultBeck, M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1021777 · Cited by 1
“This treatment led to an increase of enzyme activity in serum and in the brain, resulting in reduction of GAG accumulation, correction of lysosomal pathology of several organs, normalization of behavior and prolonged survival [57].”
BackgroundImmune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Self-citationRecent progress in gene therapies for mucopolysaccharidoses
Ginocchio, V. M., & Brunetti‐Pierri, N. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1529564 · Cited by 1
“resulted in widespread transgene expression throughout the brain [72].”
BackgroundTerapias avanzadas en enfermedades raras
Fillat, C., Río, M. D., Martínez‐Santamaría, L., & Bueren, J. A. (2018) · Arbor · doi:10.3989/arbor.2018.789n3009 · Cited by 1
Gene therapy approaches in central nervous system regenerative medicine
Bosch, A., & Chillón, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00010-6 · Cited by 1
Mylvara, A. V., Davidson, C. D., Alexander, D. M., Venditti, C. P., & Porter, F. D. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.233 · Cited by 1
“62 The BBB plays a critical role in compartmentalizing systemic and CNS immune responses.”
Gene Therapy for Neurodevelopmental Disorders
McCarty, D. M., & Fu, H. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0025276 · Cited by 1
Virus-mediated Delivery of the Fmr1 Gene as a Tool for the Treatment of Fragile X Syndrome
Moghaddam, S. G. (2016) · TSpace (University of Toronto)
Gene Therapy Approaches for Neurological Lysosomal Storage Diseases
McCurdy, V. J. (2014)
Tomasiewicz, H. C., Kocharian, G., & Kaplitt, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00030-9
Martin, M. J. (2020) · Mspace (University of Manitoba)
Therapeutic RNAi-based gene therapy for neurodegenerative disorders : slowing down the ticking clock
Martier, R. (2020) · Leiden Repository (Leiden University)
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Self-citation
Metadata
- Authors
- Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., García-Fructuoso, G., Molas, M., Maggioni, L., Muñoz, S., Motas, S., Ruberte, J., Mingozzi, F., Pumarola, M., & Bosch, F.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Children's Hospital of Philadelphia (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-07-01
- Volume
- 123
- Issue
- 8
- Pages
- 3254-3271
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3726158
- OpenAlex
- W2085717798
- Cited by
- 215
- References
- 69
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 27 · 2023: 9 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 13 · 2018: 27 · 2017: 16 · 2016: 17 · 2015: 17 · 2014: 28 · 2013: 5
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Funders
- Fundación Ramón Areces
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- MPS España
- Universitat Autònoma de Barcelona
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mucopolysaccharidosis type IIIA, lysosomal storage disease, AAV9, blood-brain barrier, heparan sulfate, glycosaminoglycan accumulation, intracerebroventricular administration, beagle dogs, mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.